163 related articles for article (PubMed ID: 9676753)
1. Clinical and immunologic effects of a PRIMATIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis: results of a phase I, single dose, dose escalating trial.
Yocum DE; Solinger AM; Tesser J; Gluck O; Cornett M; O'Sullivan F; Nordensson K; Dallaire B; Shen CD; Lipani J
J Rheumatol; 1998 Jul; 25(7):1257-62. PubMed ID: 9676753
[TBL] [Abstract][Full Text] [Related]
2. CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis.
Mason U; Aldrich J; Breedveld F; Davis CB; Elliott M; Jackson M; Jorgensen C; Keystone E; Levy R; Tesser J; Totoritis M; Truneh A; Weisman M; Wiesenhutter C; Yocum D; Zhu J
J Rheumatol; 2002 Feb; 29(2):220-9. PubMed ID: 11838838
[TBL] [Abstract][Full Text] [Related]
3. High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis.
Davis JC; Fessler BJ; Tassiulas IO; McInnes IB; Yarboro CH; Pillemer S; Wilder R; Fleisher TA; Klippel JH; Boumpas DT
J Rheumatol; 1998 Sep; 25(9):1694-704. PubMed ID: 9733448
[TBL] [Abstract][Full Text] [Related]
4. Administration of an anti-CD5 immunoconjugate to patients with rheumatoid arthritis: effect on peripheral blood mononuclear cells and in vitro immune function.
Fishwild DM; Strand V
J Rheumatol; 1994 Apr; 21(4):596-604. PubMed ID: 7518519
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double blind, placebo controlled multicenter trial of murine anti-CD4 monoclonal antibody therapy in rheumatoid arthritis.
Wendling D; Racadot E; Wijdenes J; Sibilia J; Flipo RM; Cantagrel A; Miossec P; Eschard JP; Macro M; Bertin P; Lioté F; Debiais F; Juvin R; Le Goff P; Masson C
J Rheumatol; 1998 Aug; 25(8):1457-61. PubMed ID: 9712083
[TBL] [Abstract][Full Text] [Related]
6. Treatment with a chimeric CD4 monoclonal antibody is associated with a relative loss of CD4+/CD45RA+ cells in patients with rheumatoid arthritis.
van der Lubbe PA; Breedveld FC; Tak PP; Schantz A; Woody J; Miltenburg AM
J Autoimmun; 1997 Feb; 10(1):87-97. PubMed ID: 9080303
[TBL] [Abstract][Full Text] [Related]
7. Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab.
Toubi E; Kessel A; Mahmudov Z; Hallas K; Rozenbaum M; Rosner I
Ann N Y Acad Sci; 2005 Jun; 1051():506-14. PubMed ID: 16126991
[TBL] [Abstract][Full Text] [Related]
8. Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis.
Maurice MM; van der Graaff WL; Leow A; Breedveld FC; van Lier RA; Verweij CL
Arthritis Rheum; 1999 Oct; 42(10):2166-73. PubMed ID: 10524689
[TBL] [Abstract][Full Text] [Related]
9. A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis.
Mould DR; Davis CB; Minthorn EA; Kwok DC; Elliott MJ; Luggen ME; Totoritis MC
Clin Pharmacol Ther; 1999 Sep; 66(3):246-57. PubMed ID: 10511060
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study.
Burge DJ; Bookbinder SA; Kivitz AJ; Fleischmann RM; Shu C; Bannink J
Clin Ther; 2008 Oct; 30(10):1806-16. PubMed ID: 19014836
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.
Haringman JJ; Gerlag DM; Smeets TJ; Baeten D; van den Bosch F; Bresnihan B; Breedveld FC; Dinant HJ; Legay F; Gram H; Loetscher P; Schmouder R; Woodworth T; Tak PP
Arthritis Rheum; 2006 Aug; 54(8):2387-92. PubMed ID: 16869001
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS
Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis.
Wendling D; Wijdenes J; Racadot E; Morel-Fourrier B
J Rheumatol; 1991 Mar; 18(3):325-7. PubMed ID: 1713269
[TBL] [Abstract][Full Text] [Related]
14. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.
Roll P; Palanichamy A; Kneitz C; Dorner T; Tony HP
Arthritis Rheum; 2006 Aug; 54(8):2377-86. PubMed ID: 16869000
[TBL] [Abstract][Full Text] [Related]
15. HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris.
Skov L; Kragballe K; Zachariae C; Obitz ER; Holm EA; Jemec GB; Sølvsten H; Ibsen HH; Knudsen L; Jensen P; Petersen JH; Menné T; Baadsgaard O
Arch Dermatol; 2003 Nov; 139(11):1433-9. PubMed ID: 14623703
[TBL] [Abstract][Full Text] [Related]
16. Immunologic assessment during treatment of rheumatoid arthritis with anti-CD5 immunoconjugate.
Cannon GW; Marble DA; Griffiths MM; Cole BC; McCall S; Schulman SF; Strand V
J Rheumatol; 1995 Feb; 22(2):207-13. PubMed ID: 7537827
[TBL] [Abstract][Full Text] [Related]
17. Analysis of type 1 and type 2 T cells in synovial fluid and peripheral blood of patients with rheumatoid arthritis.
Kusaba M; Honda J; Fukuda T; Oizumi K
J Rheumatol; 1998 Aug; 25(8):1466-71. PubMed ID: 9712085
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.
Davis JC; Totoritis MC; Rosenberg J; Sklenar TA; Wofsy D
J Rheumatol; 2001 Jan; 28(1):95-101. PubMed ID: 11196549
[TBL] [Abstract][Full Text] [Related]
19. Suppressor activity among CD4+,CD25++ T cells is discriminated by membrane-bound tumor necrosis factor alpha.
Wang J; van Dongen H; Scherer HU; Huizinga TW; Toes RE
Arthritis Rheum; 2008 Jun; 58(6):1609-18. PubMed ID: 18512781
[TBL] [Abstract][Full Text] [Related]
20. Nondepleting humanized anti-CD4 monoclonal antibody in patients with refractory rheumatoid arthritis.
Moreland LW; Haverty TP; Wacholtz MC; Knowles RW; Bucy RP; Heck LW; Koopman WJ
J Rheumatol; 1998 Feb; 25(2):221-8. PubMed ID: 9489810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
